Identification of new prognostic biomarkers for stage III metastatic melanoma patients

Abstract

Accurately predicting disease outcome among patients bearing Stage III metastatic melanoma is complex. However, current advances in personalized medicine call for ever more precise prognostic assessments, as these have a significant impact not only on the design and analysis of clinical trials, but also on therapeutic decision-making. © 2013 Landes Bioscience.